Faculty

Back to Index
Mitra K Nadim, MD
Professor of Clinical Medicine
Medicine
HCC II 1520 San Pablo St. Ste. 4225-C Off Campus Los Angeles
+1 323 226 7307

Overview

After graduating from UCLA Medical School, Dr. Nadim went to Boston for her internship and residency at the prestigious Beth Israel Hospital, which is affiliated with Harvard University’s School of Medicine. After completing a nephrology fellowship at Brigham and Women’s/Massachusetts General Hospital, Harvard University, Dr. Nadim returned to Southern California and currently serves as Professor of Clinical Medicine and Director of USC’s Hypertension Center. Dr. Nadim served as the Associate Program Director for the Nephrology Fellowship Program from 2003 – 2006.

Dr. Nadim’s major clinical and research interests concerns the diagnosis and management of resistant hypertension. she is currently one of the National Principal Investigators in the Rheos Pivitol Trial, which is a multicenter clinical trial looking at efficacy and safety of the Rheos system, an implantable baroreflex device, in subjects with resistant hypertension.

Dr. Nadim's clinical areas of expertise:

HYPERTENSION CLINIC

Dr. Nadim is a clinical specialist in hypertension and Director of the USC Hypertension Center. She has been an investigator in several hypertension studies, and her clinical practice has a special emphasis on resistant hypertension.

Awards

Keck School of Medicine of USC: Faculty Teaching Award, 2015

Keck School of Medicine of USC: Outstanding Year II Course Award, 2013

Keck School of Medicine: Faculty Teaching Award, 2012

Keck School of Medicine of USC: Outstanding Year II Teaching Award, 2011

Keck School of Medicine of USC: Master Teacher Award, 2011

Keck School of Medicine of USC: Outstanding Year II Course Award, 2008

Rheos Pivitol Trial : National Principal Investigator, 2008

Keck School of Medicine of USC: Outstanding Year II Teaching Award, 2007

Keck School of Medicine of USC: Medical Faculty Women's Award Research Grant, 2007

Keck School of Medicine of USC: Outstanding Year II Teaching Award, 2004

National Kidney Foundation: Volunteer/Donor Award, 1999

National Institutes of Health: National Research Service Award, 1999

Alpha Omega Alpha: Research Fellowship Award, 1992

University of California, Irvine: Cum Laude, 1990

University of California, Irvine: Excellence in Research Award, 1990

University of California, Irvine: Ooops. Something went wrong., 1990

University of California, Irvine: Phi Beta Kappa, 1989

Golden Key National Honor Society: Member, 1988

Publications

Inequity in organ allocation for patients awaiting liver transplantation: Rationale for uncapping the model for end-stage liver disease. J Hepatol. 2017 Sep; 67(3):517-525. View in: PubMed

What endpoints should be used for clinical studies in acute kidney injury? Intensive Care Med. What endpoints should be used for clinical studies in acute kidney injury? Intensive Care Med. 2017 Jun; 43(6):901-903. View in: PubMed

Sustained Reduction of Blood Pressure With Baroreceptor Activation Therapy: Results of the 6-Year Open Follow-Up. Hypertension. 2017 May; 69(5):836-843. View in: PubMed

Sustained Reduction of Blood Pressure With Baroreceptor Activation Therapy: Results of the 6-Year Open Follow-Up. Hypertension. 2017 Mar 20. View in: PubMed

What endpoints should be used for clinical studies in acute kidney injury? Intensive Care Med. What endpoints should be used for clinical studies in acute kidney injury? Intensive Care Med. 2017 Mar 02. View in: PubMed

An exploratory propensity score matched comparison of second-generation and first-generation baroreflex activation therapy systems. J Am Soc Hypertens. 2017 Feb; 11(2):81-91. View in: PubMed

Perioperative Renal Replacement Therapy in Liver Transplantation. Int Anesthesiol Clin. 2017; 55(2):81-91. View in: PubMed

An exploratory propensity score matched comparison of second-generation and first-generation baroreflex activation therapy systems. J Am Soc Hypertens. 2016 Dec 16. View in: PubMed

Kidney biomarkers in cirrhosis. J Hepatol. 2016 Oct; 65(4):809-24. View in: PubMed

Corrigendum to "Management of the critically ill patients with cirrhosis: A multidisciplinary perspective". J Hepatol. 2016 May 27. View in: PubMed

Management of Acute-on-Chronic Liver Failure. Semin Liver Dis. 2016 May; 36(2):141-52. View in: PubMed

Management of the critically ill patient with cirrhosis: A multidisciplinary perspective. J Hepatol. 2016 Mar; 64(3):717-35. View in: PubMed

Pathogenesis of Hepatorenal Syndrome: Implications for Therapy. Am J Kidney Dis. 2016 Feb; 67(2):318-28. View in: PubMed

Acute Kidney Injury in Cirrhosis. Crit Care Clin. 2015 Oct; 31(4):737-50. View in: PubMed

Hepatorenal Disorders. Chest. 2015 Aug; 148(2):550-558. View in: PubMed

Hepatorenal Disorders. Chest. 2015 Aug 1; 148(2):550-8. View in: PubMed

Renal denervation in heart failure. Curr Hypertens Rep. 2015 Apr; 17(4):528. View in: PubMed

Renal Denervation in Heart Failure. Curr Hypertens Rep. 2015 Mar; 17(3):17. View in: PubMed

Resistant hypertension: medical management and alternative therapies. Cardiol Clin. 2015 Feb; 33(1):75-87. View in: PubMed

Intraoperative hemodialysis during liver transplantation: a decade of experience. Liver Transpl. 2014 Jul; 20(7):756-64. View in: PubMed

Glomerular filtration rate equations for liver-kidney transplantation in patients with cirrhosis: validation of current recommendations. Hepatology. 2014 Apr; 59(4):1514-21. View in: PubMed

Simultaneous liver-kidney transplantation: a survey of US transplant centers. Am J Transplant. 2012 Nov; 12(11):3119-27. View in: PubMed

Simultaneous liver-kidney transplantation summit: current state and future directions. Am J Transplant. 2012 Nov; 12(11):2901-8. View in: PubMed

Living donor liver transplantation for hepatorenal syndrome: to do or not to do? That is the question. Liver Transpl. 2012 Oct; 18(10):1138-9. View in: PubMed

Impact of the etiology of acute kidney injury on outcomes following liver transplantation: acute tubular necrosis versus hepatorenal syndrome. Liver Transpl. 2012 May; 18(5):539-48. View in: PubMed

Baroreflex activation therapy provides durable benefit in patients with resistant hypertension: results of long-term follow-up in the Rheos Pivotal Trial. J Am Soc Hypertens. 2012 Mar-Apr; 6(2):152-8. View in: PubMed

Hepatorenal syndrome: the 8th International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. Crit Care. 2012 Feb 09; 16(1):R23. View in: PubMed

Medical management of hepatorenal syndrome. Nephrol Dial Transplant. 2012 Jan; 27(1):34-41. View in: PubMed

Hepatorenal syndrome: the 8th international consensus conference of the Acute Dialysis Quality Initiative (ADQI) Group. Crit Care. 2012; 16(1):R23. View in: PubMed

Baroreflex activation therapy lowers blood pressure in patients with resistant hypertension: results from the double-blind, randomized, placebo-controlled rheos pivotal trial. J Am Coll Cardiol. 2011 Aug 09; 58(7):765-73. View in: PubMed

Baroreflex activation therapy lowers blood pressure in patients with resistant hypertension: results from the double-blind, randomized, placebo-controlled rheos pivotal trial. J Am Coll Cardiol. 2011 Aug 9; 58(7):765-73. View in: PubMed

Working Party proposal for a revised classification system of renal dysfunction in patients with cirrhosis. Gut. 2011 May; 60(5):702-9. View in: PubMed

Blood-management programs: a clinical and administrative model with program implementation strategies. Perm J. 2009; 13(1):18-28. View in: PubMed

An overview of drug-induced acute kidney injury. Crit Care Med. 2008 Apr; 36(4 Suppl):S216-23. View in: PubMed

Are 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors renoprotective? J Am Soc Nephrol. Are 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors renoprotective? J Am Soc Nephrol. 2005 Mar; 16 Suppl 1:S11-7. View in: PubMed

Antihypertensive drugs and the kidney. Curr Cardiol Rep. 2004 Nov; 6(6):403-8. View in: PubMed

Powered bySC CTSI